Five things for pharma marketers to know: Thursday, January 18, 2018
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy
FDA launches digital health pre-certification pilot; J&J’s experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Pfizer receives breakthrough designation for experimental rare disease drug; Endocyte cuts 30 jobs; AbbVie RA drug meets Phase-III goals
Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals
Roche’s Actemra is already approved for three forms of arthritis.
An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.
Genzyme’s experimental enzyme-replacement therapy olipudase alfa is being investigated for the Type B form of the condition.
AbbVie expected to submit chronic lymphocytic leukemia drug venetoclax to the FDA this year.
Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.